Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $10.20.

A number of analysts have issued reports on the company. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. HC Wainwright started coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They set a “buy” rating and a $7.00 price objective for the company. Stifel Nicolaus began coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price on the stock. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Wolfe Research initiated coverage on Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective for the company.

Palisade Bio Price Performance

PALI opened at $1.92 on Thursday. The firm has a market capitalization of $333.27 million, a price-to-earnings ratio of -1.90 and a beta of 1.52. The company’s 50 day simple moving average is $1.97 and its two-hundred day simple moving average is $1.91. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.86.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, equities analysts anticipate that Palisade Bio will post -0.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Palisade Bio

A number of hedge funds have recently modified their holdings of the business. CTC Alternative Strategies Ltd. purchased a new stake in Palisade Bio in the 1st quarter valued at about $31,000. Bank of America Corp DE boosted its stake in Palisade Bio by 181.1% during the first quarter. Bank of America Corp DE now owns 197,074 shares of the company’s stock worth $345,000 after buying an additional 126,977 shares during the period. Janus Henderson Group PLC increased its position in shares of Palisade Bio by 1.4% during the first quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock valued at $18,760,000 after acquiring an additional 149,118 shares during the last quarter. ADAR1 Capital Management LLC increased its position in shares of Palisade Bio by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 2,264,845 shares of the company’s stock valued at $3,963,000 after acquiring an additional 260,000 shares during the last quarter. Finally, Orbimed Advisors LLC raised its stake in shares of Palisade Bio by 24.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock valued at $4,083,000 after acquiring an additional 461,580 shares during the period. 11.79% of the stock is currently owned by hedge funds and other institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.